Christopher Morabito - 01 Aug 2022 Form 4 Insider Report for Astria Therapeutics, Inc. (ATXS)

Reporting relationship: Chief Medical Officer
Issuer ticker: ATXS
Reported as of: 01 Aug 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Aug 2022, 08:51:17 UTC
Prior SEC filing: 15 Jul 2022
Next SEC filing: 06 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Ben Harshbarger, as attorney-in-fact for Christopher J. Morabito

Key filing fact

Christopher Morabito filed Form 4 for Astria Therapeutics, Inc. (ATXS) on 02 Aug 2022.

Key facts

This page summarizes Christopher Morabito's Form 4 filing for Astria Therapeutics, Inc. (ATXS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Aug 2022, 08:51.

Change

Previous filing in this sequence was filed on 15 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATXS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 01 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $3.87
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on August 1, 2022, pursuant to the Astria Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vesting on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.